Q&A with Jim Vaughan of 3M Drug Delivery Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Jim Vaughan of 3M Drug Delivery Systems

Pharmaceutical Technology
Volume 34, Issue 2, pp. 70


Jim Vaughan

PharmTech: Do you see a new industry trend emerging?

Vaughan: New developments in the Asia–Pacific region have been interesting to follow. In 2009, for the first time, most of the world’s bioscience degrees were awarded to people outside the United States, and we are certainly seeing the changes that is bringing about. The explosion of startups, particularly in Asia, is one of the key factors in our expansion of laboratory facilities. Our new laboratory in Singapore supports earlystage product development and late-stage regulatory data demands, so we are able to serve new and established pharmaceutical companies in that region. We expect this laboratory to become a major research hub, in addition to our research locations in the US and United Kingdom. An additional trend is the expansion of microneedle technology, in which we are seeing increased interest. At 3M, we have long experience with this technology and we feel well positioned, with our solid and hollow, microstructured transdermal systems, to meet the new demands for these applications.

PharmTech: What is the most common demand your clients are currently making of you?

Vaughan: Our clients are looking for innovation in drug delivery and new ways to administer their products. Our chief technologies are in the areas of inhalation and transdermal delivery, so we are often called upon to adapt drug products to these methods. The capabilities of both technologies are expanding, and the inhalation market is growing to include larger molecules than before, including proteins and peptides. Inhalation is a promising delivery route for local and systemic drug delivery. The number of transdermal therapies is growing steadily as well. We have created a method of solid microneedle delivery that expands the range of medications that can be delivered transdermally to patients, including vaccines, proteins, and peptides. We also are working on a hollow, microstructured transdermal system that will further expand the range of medications for which transdermal systems can be used.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here